

Comparing stereotactic ablative radiotherapy (SABR) versus chemoembolization (re-TACE) for hepatocellular carcinoma: response after initial TACE (TASABR): a randomized controlled trial

BMC Cancer

19, 275

DOI: [10.1186/s12885-019-5461-3](https://doi.org/10.1186/s12885-019-5461-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). <i>Cancers</i> , 2019, 11, 1085.	1.7	60
2	Oxygen-Challenge Blood Oxygen Level-Dependent Magnetic Resonance Imaging for Evaluation of Early Change of Hepatocellular Carcinoma to Chemoembolization: A Feasibility Study. <i>Academic Radiology</i> , 2021, 28, S13-S19.	1.3	3
3	Transcription factor IRX5 promotes hepatocellular carcinoma proliferation and inhibits apoptosis by regulating the p53 signalling pathway. <i>Cell Biochemistry and Function</i> , 2020, 38, 621-629.	1.4	11
4	Stereotactic Body Radiation Therapy vs. Transarterial Chemoembolization in Inoperable Barcelona Clinic Liver Cancer Stage a Hepatocellular Carcinoma: A Retrospective, Propensity-Matched Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 347.	1.3	27
5	Clinical Effect of Iodine-125 Seed Implantation in Patients with Primary Liver Cancer and Its Effect on Th1/Th2 Cells in Peripheral Blood. <i>Journal of Oncology</i> , 2021, 2021, 1-6.	0.6	5
6	Salt-inducible kinase 2 functions as a tumor suppressor in hepatocellular carcinoma. <i>Environmental Toxicology</i> , 2021, 36, 2530-2540.	2.1	5
8	Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAETACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360). <i>Current Oncology</i> , 2022, 29, 8802-8813.	0.9	11
9	TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial. <i>JHEP Reports</i> , 2023, 5, 100689.	2.6	1
10	Effectiveness of c-TACE Combined With Sorafenib Versus c-TACE Monotherapy in Advanced Hepatocellular Carcinoma: A Retrospective Study. <i>Clinical Medicine Insights: Oncology</i> , 2023, 17, 117955492211466.	0.6	2